Elsevier

The Annals of Thoracic Surgery

Volume 92, Issue 5, November 2011, Pages 1780-1787
The Annals of Thoracic Surgery

Original article
General thoracic
Pulmonary Resection of Metastatic Sarcoma: Prognostic Factors Associated With Improved Outcomes

Presented at the Forty-seventh Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Jan 31–Feb 2, 2011.
https://doi.org/10.1016/j.athoracsur.2011.05.081Get rights and content

Background

There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes.

Methods

Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model.

Results

Overall 5-year survival for the cohort was 50.1%. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41%; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22% versus 68% ;p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival.

Conclusions

Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.

Section snippets

Patients and Methods

Ninety-seven patients underwent pulmonary resection for metastatic sarcoma at the Massachusetts General Hospital from June 2002 to December 2008. The study was approved by the Massachusetts General Hospital Institutional Review Board. All patients included in this study demonstrated complete local control of the primary sarcoma and exhibited isolated pulmonary metastases at the time of pulmonary resection. Pulmonary metastases were confirmed pathologically and the histologic features of the

Results

Eighty-nine patients were identified with metastatic sarcoma to the lung with nearly equal male-female distribution (42:47). The mean age for patients at the time of first pulmonary resection was 51 years. A total of 134 pulmonary resections were performed. The histologic type and frequency distribution are illustrated in Figure 1. Osteosarcoma was the most common histologic subtype (19%), followed by malignant fibrous histiocytoma (17%), leiomyosarcoma (15%), and chondrosarcoma (11%). No

Comment

Although the development of metastatic sarcoma in the lung portends a poor prognosis, metastasectomy offers long-term survival for selected patients. Since neither chemotherapy nor radiation has shown effectiveness [11], and in the absence of prospective studies comparing resection to other treatment, many patients are faced with limited options. We retrospectively reviewed our experience with pulmonary metastasectomy in either soft tissue or bone sarcoma. Overall 5-year survival in this highly

References (21)

There are more references available in the full text version of this article.

Cited by (0)

View full text